Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 14 Nov 23 EFFECT Notice of effectiveness
- 8 Nov 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
18 Oct 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 28 Sep 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 18 Aug 23 S-4 Registration of securities issued in business combination transactions
NGNE similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement No. 333-274095 on Form S-4 of our report dated March 20, 2023 (and September 28, 2023, as to the effects of the reverse stock split), relating to the financial statements of Neoleukin Therapeutics, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
Seattle, Washington
October 18, 2023